Document Detail


Drug-eluting stent for the treatment of small coronary lesion: comparison between sirolimus- and paclitaxel-eluting stent.
MedLine Citation:
PMID:  17442204     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Patients with small coronary lesions are at increased risk for repeat interventions after coronary angioplasty and stenting. The efficacy of drug-eluting stents (DES) has been demonstrated to improve the outcomes of these patients and is a focus of interest. Currently, two platforms of DES are available (sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES)). However, it has less been known that DES, SES vs PES, is superior for the treatment of small coronary lesions. METHODS: In this retrospective study, 87 consecutive patients with 151 lesions underwent implantation of coronary SES (n = 68) and PES (n = 83). Quantitative coronary angiography (QCA) was performed at the time of stent implantation and subsequently at 8 months post-stenting. Small vessel disease was defined as lesions in vessels with diameter 2.5 mm measured by QCA. Major adverse cardiac events (MACE) including death, thrombosis, nonfatal myocardial infarction and target lesion revascularization (TLR) were compared between the two groups. RESULTS: Baseline clinical characteristics and angiographic parameters were similar between the two groups. At clinical and angiographic follow-up, overall thrombosis rates were similar in both groups (0 vs 1.2%, P > 0.05). The TLR and in-segment restenosis were not significantly different (19.1% vs 25.3%; 10.3% vs 10.8%, P = 0.365 and P = 0.913 respectively) between the two groups. The in-stent restenosis rate, however, was significantly higher in the PES group (4.4% vs 21.7%; P = 0.002). Similarly, the late loss was significantly higher in the PES group ((0.140.38) mm vs (0.490.61) mm; P < 0.001). CONCLUSIONS: In this small sample-size, non-randomized study, the data indicated that implantation of SES for the treatment of patients with small coronary lesion showed more favorable results in respect of restenosis compared with PES implantation.
Authors:
Jian-jun Li; Bo Xu; Yue-jin Yang; Ji-lin Chen; Shu-bin Qiao; Wei-Hua Ma; Xue-wen Qin; Min Yao; Hai-bo Liu; Yong-jian Wu; Jin-qing Yuan; Jue Chen; Shi-jie You; Jun Dai; Ran Xia; Run-lin Gao
Related Documents :
9669254 - Stent implantation versus balloon angioplasty in chronic coronary occlusions: results f...
17569804 - A quantitative estimate of bare-metal stenting compared with balloon angioplasty in pat...
15939104 - The sv stent study: a prospective, multicentre, angiographic evaluation of the biodivys...
9583284 - Comparison of in-hospital and follow-up results of directional atherectomy and stenting...
12930274 - Factors affecting ventricular function and survival after partial left ventriculectomy.
16030484 - Anatomical repair of partially unroofed coronary sinus syndrome through the coronary si...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Chinese medical journal     Volume:  120     ISSN:  0366-6999     ISO Abbreviation:  Chin. Med. J.     Publication Date:  2007 Apr 
Date Detail:
Created Date:  2007-04-19     Completed Date:  2007-05-11     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7513795     Medline TA:  Chin Med J (Engl)     Country:  China    
Other Details:
Languages:  eng     Pagination:  569-73     Citation Subset:  IM    
Affiliation:
Department of Cardiology, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China. lijnjn@yahoo.com.cn
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Angioplasty, Transluminal, Percutaneous Coronary / methods*
Coronary Angiography
Coronary Disease / therapy*
Coronary Restenosis / prevention & control
Drug Delivery Systems
Female
Humans
Male
Middle Aged
Paclitaxel / administration & dosage*
Retrospective Studies
Sirolimus / administration & dosage*
Stents*
Chemical
Reg. No./Substance:
33069-62-4/Paclitaxel; 53123-88-9/Sirolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Left ventricular endocardial pacing predicts the reduction of left ventricular outflow tract pressur...
Next Document:  A comparison of clinical and angiographic outcomes after Excel bioabsorbable polymer versus Firebird...